Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 6/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.84 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.84 |
| ▸ | PTGFR | P43088 | 4/20 | 0.84 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PTGIR | P43119 | 2/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.60 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.60 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nocloprost SCHEMBL1554645 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL436204 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL9847683 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL1554648 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL10803435 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL9480879 | 0.95 | PTGER3 (0.76) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL11484121 | 0.91 | PTGFR (1.00) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL3366405 | 0.91 | PTGFR (1.00) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL10774699 | 0.91 | PTGFR (0.68) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL9481875 | 0.90 | PTGFR (0.68) | PTGER3TBXA2RPTGER1PTGFRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0243369-B1 | 9-HALOGEN PROSTAGLANDINE CLATHRATES AND UTILIZATION THEREOF AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-03-18 | — | — | EP | claimed |
| US-5095010-A | ANTIGESTAGENS, GLUCOCORTICOIDS AND PROSTAGLANDINS FOR INDUCTION OF LABOR OR FOR TERMINATION OF PREGNANCY | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | claimed |
| US-5079259-A | PHARMACEUTICALLY ACTIVE 9-CHLOROPROSTAGLANDINS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-07 | — | — | US | claimed |
| US-5047525-A | With cyclodextrin ty | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | claimed |
| US-4626531-A | Prostaglandins and antigestagens for induction of labor and for abortion | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-12-02 | — | — | US | claimed |
| EP-0030377-B1 | 9-CHLORO-PROSTAGLANDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AS MEDICINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-02-22 | — | — | EP | claimed |
| US-7563924-B2 | 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-07-21 | — | — | US | disclosed |
| EP-1816121-B1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070203096-A1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-08-30 | — | — | US | disclosed |
| EP-1816121-A1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-6780504-B2 | COVERING, ACTIVE MATERIAL AND ADHESIVE; SPRAYING | GRUENENTHAL GMBH (DE) | 2004-08-24 | — | — | US | disclosed |
| US-20020142036-A1 | Covering, active material and adhesive; spraying | GRUENENTHAL GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
| US-5204371-A | Pharmaceutically active 9-chloroprostaglandins | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-04-20 | — | — | US | disclosed |
| US-5095010-A | ANTIGESTAGENS, GLUCOCORTICOIDS AND PROSTAGLANDINS FOR INDUCTION OF LABOR OR FOR TERMINATION OF PREGNANCY | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | disclosed |
| US-5079259-A | PHARMACEUTICALLY ACTIVE 9-CHLOROPROSTAGLANDINS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-07 | — | — | US | disclosed |
| US-5047525-A | With cyclodextrin ty | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0243369-A1 | 9-HALOGEN PROSTAGLANDINE CLATHRATES AND UTILIZATION THEREOF AS DRUGS. | SCHERING AG (DE) | 1987-11-04 | — | — | EP | disclosed |
| US-4626531-A | Prostaglandins and antigestagens for induction of labor and for abortion | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-12-02 | — | — | US | disclosed |
| WO-1986004504-A1 | 9-HALOGEN PROSTAGLANDINE CLATHRATES AND UTILIZATION THEREOF AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-08-14 | — | — | WO | disclosed |
| US-4444788-A | Pharmaceutically active 9-chloroprostaglandins | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203096-A1 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | PGF, PTGIS, CYP11B2 | PTGER3 62/4885TBXA2R 91/4885PTGER1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.